Literature DB >> 20935265

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Anna Maria Calcagno1, Crystal D Salcido, Jean-Pierre Gillet, Chung-Pu Wu, Jennifer M Fostel, Melanie D Mumau, Michael M Gottesman, Lyuba Varticovski, Suresh V Ambudkar.   

Abstract

BACKGROUND: Cancer stem cells are presumed to have virtually unlimited proliferative and self-renewal abilities and to be highly resistant to chemotherapy, a feature that is associated with overexpression of ATP-binding cassette transporters. We investigated whether prolonged continuous selection of cells for drug resistance enriches cultures for cancer stem-like cells.
METHODS: Cancer stem cells were defined as CD44+/CD24⁻ cells that could self-renew (ie, generate cells with the tumorigenic CD44+/CD24⁻ phenotype), differentiate, invade, and form tumors in vivo. We used doxorubicin-selected MCF-7/ADR cells, weakly tumorigenic parental MCF-7 cells, and MCF-7/MDR, an MCF-7 subline with forced expression of ABCB1 protein. Cells were examined for cell surface markers and side-population fractions by microarray and flow cytometry, with in vitro invasion assays, and for ability to form mammospheres. Xenograft tumors were generated in mice to examine tumorigenicity (n = 52). The mRNA expression of multidrug resistance genes was examined in putative cancer stem cells and pathway analysis of statistically significantly differentially expressed genes was performed. All statistical tests were two-sided.
RESULTS: Pathway analysis showed that MCF-7/ADR cells express mRNAs from ABCB1 and other genes also found in breast cancer stem cells (eg, CD44, TGFB1, and SNAI1). MCF-7/ADR cells were highly invasive, formed mammospheres, and were tumorigenic in mice. In contrast to parental MCF-7 cells, more than 30% of MCF-7/ADR cells had a CD44+/CD24⁻ phenotype, could self-renew, and differentiate (ie, produce CD44+/CD24⁻ and CD44+/CD24+ cells) and overexpressed various multidrug resistance-linked genes (including ABCB1, CCNE1, and MMP9). MCF-7/ADR cells were statistically significantly more invasive in Matrigel than parental MCF-7 cells (MCF-7 cells = 0.82 cell per field and MCF-7/ADR = 7.51 cells per field, difference = 6.69 cells per field, 95% confidence interval = 4.82 to 8.55 cells per field, P < .001). No enrichment in the CD44+/CD24⁻ or CD133+ population was detected in MCF-7/MDR.
CONCLUSION: The cell population with cancer stem cell characteristics increased after prolonged continuous selection for doxorubicin resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935265      PMCID: PMC2970576          DOI: 10.1093/jnci/djq361

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  69 in total

1.  Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53.

Authors:  F Pirnia; M Breuleux; E Schneider; M Hochmeister; S E Bates; A Marti; M A Hotz; D C Betticher; M M Borner
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

2.  ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis.

Authors:  Shuyang Sun; Zuolin Wang
Journal:  Biochem Biophys Res Commun       Date:  2010-05-05       Impact factor: 3.575

3.  Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5).

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Stephen B Hladky; Suresh V Ambudkar; Margery A Barrand
Journal:  FEBS J       Date:  2005-09       Impact factor: 5.542

4.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Carole Tarpin; Mark Diebel; Benjamin Esterni; Gilles Houvenaeghel; Jean-Marc Extra; François Bertucci; Jocelyne Jacquemier; Luc Xerri; Gabriela Dontu; Giorgio Stassi; Yi Xiao; Sanford H Barsky; Daniel Birnbaum; Patrice Viens; Max S Wicha
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

Review 6.  RAD51, genomic stability, and tumorigenesis.

Authors:  Christine Richardson
Journal:  Cancer Lett       Date:  2005-02-10       Impact factor: 8.679

7.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

8.  Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase.

Authors:  Matthew R Clay; Mark Tabor; John Henry Owen; Thomas E Carey; Carol R Bradford; Gregory T Wolf; Max S Wicha; Mark E Prince
Journal:  Head Neck       Date:  2010-09       Impact factor: 3.147

9.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

10.  Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Authors:  Daniel J Pearce; David Taussig; Catherine Simpson; Kirsty Allen; Ama Z Rohatiner; T Andrew Lister; Dominique Bonnet
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

View more
  109 in total

1.  The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

Authors:  Kaustubh N Bhinge; Vineet Gupta; Salman B Hosain; Seetharama D Satyanarayanajois; Sharon A Meyer; Benny Blaylock; Qian-Jin Zhang; Yong-Yu Liu
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

2.  Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Authors:  Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Miguel Marino; Lisa J Green; Meena I Vora; Chirayu Patel; Josiah N Orina; Tatiana A Eliseeva; Vineet Singal; Raji Padmanabhan; Ben Davidson; Ram Ganapathi; Anil K Sood; Bo R Rueda; Suresh V Ambudkar; Michael M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-08       Impact factor: 11.205

3.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

4.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

5.  MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.

Authors:  J Lu; G Song; Q Tang; J Yin; C Zou; Z Zhao; X Xie; H Xu; G Huang; J Wang; D-F Lee; R Khokha; H Yang; J Shen
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

6.  Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells.

Authors:  Hira Lal Goel; Tatiana Gritsko; Bryan Pursell; Cheng Chang; Leonard D Shultz; Dale L Greiner; Jens Henrik Norum; Rune Toftgard; Leslie M Shaw; Arthur M Mercurio
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

Review 7.  Basement membrane matrix (BME) has multiple uses with stem cells.

Authors:  Irina Arnaoutova; Jay George; Hynda K Kleinman; Gabriel Benton
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

8.  Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.

Authors:  Meriam Ayadi; Anaïs Bouygues; Djamila Ouaret; Nathalie Ferrand; Salem Chouaib; Jean-Paul Thiery; Christian Muchardt; Michèle Sabbah; Annette K Larsen
Journal:  Oncotarget       Date:  2015-07-30

9.  Illuminating the lateral organization of cell-surface CD24 and CD44 through plasmon coupling between Au nanoparticle immunolabels.

Authors:  Xinwei Yu; Jing Wang; Amin Feizpour; Björn M Reinhard
Journal:  Anal Chem       Date:  2013-01-22       Impact factor: 6.986

10.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.